A Phase I/II Clinical Trial Of Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable (Stage III) Lung Cancers

Inclusion Criteria:

- Histologically confirmed lung cancer, excluding small cell carcinoma

- Inoperable stage I (T1-2N0) and II (T1-2N1, T3N0) disease, or stage IIIA (T3N1
andT1-3N2M0) and IIIB (TxN3M0, T4NxM0) diseases according to the American Joint
Committee of Cancer criteria 1998

- The primary tumor must be radiographically measurable.

- Age > 18.

- Karnofsky performance status > 70.

- FEV1 sufficient for patients to tolerate radiation therapy which is at the discretion
of the radiation oncologist, usually > 800 ml

- Labs: WBC > 3000; platelet count > 100,000; serum creatinine < 1.5 mg/dl or
creatinine clearance >60 ml/min.

- Laboratory values must be obtained < 3 weeks prior to registration.

- A signed informed consent.

- Patients who failed prior chemotherapy are eligible. Patients with prior radiotherapy
to the chest region are eligible as long as the normal tissue tolerance is not
violated by repeat radiotherapy.

Exclusion Criteria:

- Patients with medical contraindication to chemotherapy or radiotherapy.

- Patients with myocardial infarction within the preceding six months or symptomatic
heart disease, including uncontrolled or unstable angina, uncontrolled congestive
heart failure, and uncontrolled arrhythmia.

- Women who are pregnant.

- Patients with small cell carcinoma or mesothelioma